Targeted nanoparticles reduce tumor scarring and enable immunotherapy response in mice

AI Summary

Researchers have developed targeted nanoparticles that reduce tumor scarring and enhance immunotherapy responses in mice. This breakthrough targets the immune suppression caused by scarring in chronic diseases such as hepatitis and cirrhosis, potentially improving cancer treatment outcomes.

Many liver and lung cancers arise in tissue that's already been scarred by chronic disease, such as hepatitis, cirrhosis or long-term lung damage. That scarring creates an environment that suppresses nearby immune cells, so by the time a tumor takes hold, it's often already shielded from the immune system and immunotherapy.